Cholangiolocellular Component Predicts a Biologically Distinct Subgroup of Mass-Forming Intrahepatic...

Area of Science:

• Hepatobiliary pathology
• Molecular oncology
• Cancer genomics

Background:

• Cholangiolocellular carcinoma (CLC) is a rare variant of primary liver cancer.
• Intrahepatic cholangiocarcinomas (iCCAs) often include a CLC component, but their distinct biological features are unknown.
• Understanding these differences is crucial for accurate diagnosis and prognosis.

Purpose of the Study:

• To investigate the clinicopathological and genetic characteristics of intrahepatic cholangiocarcinomas (iCCAs) based on the presence or absence of a cholangiolocellular carcinoma (CLC) component.
• To identify distinct molecular subtypes of iCCA and their correlation with prognosis and angiogenesis.
• To explore potential therapeutic targets based on molecular differences.

Main Methods:

• Histopathological classification of 36 mass-forming iCCAs (MF-iCCAs) into CLC-positive (CLC+) and CLC-negative (CLC-) groups.
• Gene expression profiling to identify highly expressed genes in CLC(+) and CLC(-) iCCAs.
• Clinicopathological analysis, including overall survival and somatic gene alterations.
• Immunohistochemical analysis of SPP1 (osteopontin) expression.

Main Results:

• Two genetic subgroups of iCCA were identified: iCCA-G1 (CLC-related) and iCCA-G2 (non-CLC-related).
• CLC(+) iCCA (iCCA-G1) exhibited better overall survival, with upregulated stromal- and oxidation-related genes.
• CLC(-) iCCA (iCCA-G2) showed increased proliferation- and hypoxia-related genes. Angiogenesis-related genes and tumor vessel counts were higher in iCCA-G1.
• SPP1 (osteopontin) was identified as a highly expressed angiogenesis-related gene in CLC(+) iCCA.

Conclusions:

• The presence of a CLC component in MF-iCCA defines a distinct genetic subgroup (iCCA-G1) with a favorable prognosis and high angiogenesis.
• iCCA-G1 displays different gene alteration patterns and carcinogenic pathways compared to CLC(-) iCCA (iCCA-G2).
• Osteopontin expression can serve as a histopathological marker for classifying iCCA subtypes and predicting prognosis.